{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:40:24Z","timestamp":1792701624878,"version":"4.5.0"},"reference-count":87,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2003,11,1]],"date-time":"2003-11-01T00:00:00Z","timestamp":1067644800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2003,11,1]],"date-time":"2003-11-01T00:00:00Z","timestamp":1067644800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2003,11]]},"DOI":"10.4158\/ep.9.6.544","type":"journal-article","created":{"date-parts":[[2013,4,5]],"date-time":"2013-04-05T23:44:54Z","timestamp":1365205494000},"page":"544-564","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":291,"title":["American Association of Clinical Endocrinologists Medical Guidelines For Clinical Practice For The Prevention and Treatment of Postmenopausal Osteoporosis: 2001 Edition, With Selected Updates For 2003"],"prefix":"10.1016","volume":"9","author":[{"given":"Stephen F.","family":"Hodgson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelson B.","family":"Watts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Bilezikian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart L.","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. Kenney","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"C.","family":"Conrad Johnston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kleerekoper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Lindsay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjorie M.","family":"Luckey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"McClung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard R.","family":"Nankin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven M.","family":"Petak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert R.","family":"Recker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald A.","family":"Bergman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary T.","family":"Bloomgarden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Dickey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale J.","family":"Palumbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne L.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herbert I.","family":"Rettinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena W.","family":"Rodbard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harvey A.","family":"Rubenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.4158\/EP.9.6.544_bb0005","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1007\/s002239900173","article-title":"Development of clinical practice guidelines for prevention and treatment of osteoporosis","volume":"59","author":"Johnston","year":"1996","journal-title":"Calcif Tissue Int."},{"issue":"Suppl 4","key":"10.4158\/EP.9.6.544_bb0010","first-page":"S3","article-title":"diagnosis and treatment and cost-effectiveness analysis [executive summary]","volume":"8","author":"Osteoporosis: review of the evidence for prevention","year":"1998","journal-title":"Osteoporos Int"},{"key":"10.4158\/EP.9.6.544_bb0015","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1001\/jama.283.10.1318","article-title":"(Fracture Intervention Trial Research Group). Monitoring osteoporosis therapy with bone densitometry: misleading changes and regression to the mean","volume":"283","author":"Cummings","year":"2000","journal-title":"JAMA."},{"key":"10.4158\/EP.9.6.544_bb0020","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0378-5122(96)01079-1","article-title":"Perimenopausal bone density screening\u2014will it help prevent osteoporosis?","volume":"26","author":"Garton","year":"1997","journal-title":"Maturitas."},{"key":"10.4158\/EP.9.6.544_bb0025","doi-asserted-by":"crossref","first-page":"187","DOI":"10.7326\/0003-4819-124-2-199601150-00001","article-title":"Fox KM (Osteoporotic Fractures Research Group). Axial bone mass in older women","volume":"124","author":"Orwoll","year":"1996","journal-title":"Ann Intern Med."},{"key":"10.4158\/EP.9.6.544_bb0030","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1210\/jcem.85.1.6267","article-title":"Antifracture efficacy of antire- sorptive agents are related to changes in bone density","volume":"85","author":"Wasnich","year":"2000","journal-title":"J Clin Endocrinol Metab."},{"key":"10.4158\/EP.9.6.544_bb0035","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1385\/JCD:2:3:211","article-title":"Understanding the bone mass measurement act","volume":"2","author":"Watts","year":"1999","journal-title":"J Clin Densitom."},{"key":"10.4158\/EP.9.6.544_bb0040","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0889-8529(05)70007-4","article-title":"Biochemical markers of bone turnover: applications for osteoporosis","volume":"27","author":"Garnero","year":"1998","journal-title":"Endocrinol Metab Clin North Am."},{"key":"10.4158\/EP.9.6.544_bb0045","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1359\/jbmr.1998.13.7.1124","article-title":"Response of biochemical markers of bone turnover to hormone replacement therapy: impact of biological variability","volume":"13","author":"Hannon","year":"1998","journal-title":"J Bone Miner Res."},{"key":"10.4158\/EP.9.6.544_bb0050","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s001980070088","article-title":"Clinical use of biochemical markers of bone remodeling: current status and future directions","volume":"11","author":"Looker","year":"2000","journal-title":"Osteoporos Int."},{"key":"10.4158\/EP.9.6.544_bb0055","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"(Fracture Intervention Trial Research Group). Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures","volume":"348","author":"Black","year":"1996","journal-title":"Lancet"},{"key":"10.4158\/EP.9.6.544_bb0060","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1210\/jcem.85.11.6953","article-title":"(FIT Research Group). Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial","volume":"85","author":"Black","year":"2000","journal-title":"J Clin Endocrinol Metab."},{"key":"10.4158\/EP.9.6.544_bb0065","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","article-title":"Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial","volume":"280","author":"Cummings","year":"1998","journal-title":"JAMA."},{"key":"10.4158\/EP.9.6.544_bb0070","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1056\/NEJM199610033351403","article-title":"Esophagitis associated with the use of alendronate","volume":"335","author":"de Groen","year":"1996","journal-title":"N Engl J Med."},{"key":"10.4158\/EP.9.6.544_bb0075","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/8756-3282(95)00436-X","article-title":"Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis [erratum in Bone. 1996;19:78]","volume":"18","author":"Devogelaer","year":"1996","journal-title":"Bone."},{"key":"10.4158\/EP.9.6.544_bb0080","first-page":"1783","article-title":"Comparison of alendronate and intranasal calcitonin for treatment of osteoporosis in postmenopausal women","volume":"85","author":"Downs","year":"2000","journal-title":"J Clin Endocrinol Metab."},{"key":"10.4158\/EP.9.6.544_bb0085","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1001\/archinte.1997.00440430099012","article-title":"Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial","volume":"157","author":"Ensrud","year":"1997","journal-title":"Arch Intern Med."},{"key":"10.4158\/EP.9.6.544_bb0090","first-page":"35","article-title":"Gowan W (Fosamax International Trial [FOSIT] Study Group)","volume":"31","author":"Felsenberg","year":"1998","journal-title":"Placebo-controlled multicenter study of oral alendronate in postmenopausal osteoporotic women. Maturitas."},{"key":"10.4158\/EP.9.6.544_bb0095","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1056\/NEJM199802193380801","article-title":"(Early Postmenopausal Intervention Cohort Study Group). Prevention of bone loss with alendronate in postmenopausal women under 60 years of age","volume":"338","author":"Hosking","year":"1998","journal-title":"N Engl J Med."},{"key":"10.4158\/EP.9.6.544_bb0100","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1001\/jama.1997.03540380073035","article-title":"(Alendronate Osteoporosis Treatment Study Groups). Prevention of nonvertebral fractures by alendronate: a meta-analysis","volume":"277","author":"Karpf","year":"1997","journal-title":"JAMA."},{"key":"10.4158\/EP.9.6.544_bb0105","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1056\/NEJM199511303332201","article-title":"(Alendronate Phase III Osteoporosis Treatment Study Group). Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis","volume":"333","author":"Liberman","year":"1995","journal-title":"N Engl J Med."},{"key":"10.4158\/EP.9.6.544_bb0110","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/j.1572-0241.2000.01835.x","article-title":"Upper gastrointestinal toxicity of alendronate","volume":"95","author":"Lowe","year":"2000","journal-title":"Am J Gastroenterol."},{"key":"10.4158\/EP.9.6.544_bb0115","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/PL00004171","article-title":"(Fosamax International Trial Study Group). Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study","volume":"9","author":"Pols","year":"1999","journal-title":"Osteoporos Int."},{"key":"10.4158\/EP.9.6.544_bb0120","first-page":"1492","article-title":"(Alendronate Osteoporosis Prevention Study Group). Alendronate in early postmenopausal women: effects on bone mass during long-term treatment and after withdrawal","volume":"85","author":"Ravn","year":"2000","journal-title":"J Clin Endocrinol Metab."},{"key":"10.4158\/EP.9.6.544_bb0125","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S0016-5107(98)70256-1","article-title":"Alendronate-associated esophagitis: endoscopic and pathologic features","volume":"47","author":"Ribeiro","year":"1998","journal-title":"Gastrointest Endosc."},{"key":"10.4158\/EP.9.6.544_bb0130","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1056\/NEJM199807303390502","article-title":"(Glucocorticoid- Induced Osteoporosis Intervention Study Group). Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis","volume":"339","author":"Saag","year":"1998","journal-title":"N Engl J Med."},{"key":"10.4158\/EP.9.6.544_bb0135","first-page":"1","article-title":"(Alendronate Once-Weekly Study Group). Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis","volume":"12","author":"Schnitzer","year":"2000","journal-title":"Aging (Milano)."},{"key":"10.4158\/EP.9.6.544_bb0140","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0002-9343(97)00130-7","article-title":"Increments in bone mineral density of the lumbar spine and hip and suppression of bone turnover are maintained after discontinuation of alendronate in postmenopausal women","volume":"103","author":"Stock","year":"1997","journal-title":"Am J Med."},{"key":"10.4158\/EP.9.6.544_bb0145","first-page":"3109","article-title":"(Phase III Osteoporosis Treatment Study Group). Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women","volume":"85","author":"Tonino","year":"2000","journal-title":"J Clin Endocrinol Metab."},{"key":"10.4158\/EP.9.6.544_bb0150","first-page":"51","article-title":"The clinical tolerabil- ity profile of alendronate","volume":"101","author":"Watts","year":"1999","journal-title":"Int J Clin Pract Suppl."},{"key":"10.4158\/EP.9.6.544_bb0155","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1002\/1529-0131(199911)42:11<2309::AID-ANR8>3.0.CO;2-K","article-title":"Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study","volume":"42","author":"Cohen","year":"1999","journal-title":"Arthritis Rheum."},{"key":"10.4158\/EP.9.6.544_bb0160","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s001980070122","article-title":"Prevention of bone loss with risedronate in glucocorticoid-treated rheumatoid arthritis patients","volume":"11","author":"Eastell","year":"2000","journal-title":"Osteoporos Int."},{"key":"10.4158\/EP.9.6.544_bb0165","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial","volume":"282","author":"Harris","year":"1999","journal-title":"JAMA"},{"key":"10.4158\/EP.9.6.544_bb0170","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM200102013440503","article-title":"(Hip Intervention Program Study Group). Effect of rised- ronate on the risk of hip fracture in elderly women","volume":"344","author":"McClung","year":"2001","journal-title":"N Engl J Med."},{"key":"10.4158\/EP.9.6.544_bb0175","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s001980050010","article-title":"(Vertebral Efficacy with Risedronate Therapy [VERT] Study Group). Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis","volume":"11","author":"Reginster","year":"2000","journal-title":"Osteoporos Int."},{"key":"10.4158\/EP.9.6.544_bb0180","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1359\/jbmr.2000.15.6.1006","article-title":"Efficacy and safety of daily risedronate in the treatment of cortico steroid-induced osteoporosis in men and women: a randomized trial; European Corticosteroid-Induced Osteoporosis Treatment Study","volume":"15","author":"Reid","year":"2000","journal-title":"J Bone Miner Res."},{"key":"10.4158\/EP.9.6.544_bb0185","first-page":"S136","article-title":"Risedronate reduces vertebral fracture risk after the first year of treatment in postmenopausal women with established osteoporosis","volume":"14","author":"Watts","year":"1999","journal-title":"J Bone Miner Res."},{"key":"10.4158\/EP.9.6.544_bb0190","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1359\/jbmr.1997.12.1.103","article-title":"Short-term intravenous bisphosphonates in prevention of postmenopausal bone loss","volume":"12","author":"Heikkinen","year":"1997","journal-title":"J Bone Miner Res."},{"key":"10.4158\/EP.9.6.544_bb0195","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1007\/BF01629581","article-title":"Role of oral pamidronate in preventing bone loss in postmenopausal women","volume":"6","author":"Lees","year":"1996","journal-title":"Osteoporos Int."},{"key":"10.4158\/EP.9.6.544_bb0200","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0002-9343(97)00278-7","article-title":"Cyclical etidronate in the treatment of postmenopausal osteoporosis: efficacy and safety after seven years of treatment [erratum in Am J Med. 1998;104:608]","volume":"103","author":"Miller","year":"1997","journal-title":"Am J Med."},{"key":"10.4158\/EP.9.6.544_bb0205","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1046\/j.1365-2265.1997.d01-1741.x","article-title":"Effects of prolonged bisphosphonate therapy and its discontinuation on bone mineral density in post-menopausal osteoporosis","volume":"46","author":"Orr-Walker","year":"1997","journal-title":"Clin Endocrinol (Oxf)."},{"key":"10.4158\/EP.9.6.544_bb0210","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/0378-5122(96)01118-8","article-title":"Cyclical pamidronate infusions in postmenopausal osteoporosis","volume":"25","author":"Peretz","year":"1996","journal-title":"Maturitas."},{"key":"10.4158\/EP.9.6.544_bb0215","first-page":"S209","article-title":"A new treatment paradigm: quarterly injections of ibandronate reduce the risk of fractures in women with postmenopausal osteoporosis (PMO): results of a 3-year trial","volume":"11","author":"Recker","year":"2000","journal-title":"Osteoporos Int."},{"key":"10.4158\/EP.9.6.544_bb0220","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1210\/jcem.83.4.4742","article-title":"(Ciblos Study Group). Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid-induced bone loss","volume":"83","author":"Roux","year":"1998","journal-title":"J Clin Endocrinol Metab."},{"key":"10.4158\/EP.9.6.544_bb0225","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0889-8529(05)70014-1","article-title":"Treatment of osteoporosis with bisphospho- nates","volume":"27","author":"Watts","year":"1998","journal-title":"Endocrinol Metab Clin North Am."},{"key":"10.4158\/EP.9.6.544_bb0230","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0002-9343(00)00490-3","article-title":"A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the Prevent Recurrence of Osteoporotic Fractures Study","volume":"109","author":"Chesnut","year":"2000","journal-title":"Am J Med."},{"key":"10.4158\/EP.9.6.544_bb0235","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1001\/jama.1996.03540170033029","article-title":"Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen\/progestin interventions (PEPI) trial","volume":"276","author":"Bush","year":"1996","journal-title":"JAMA."},{"key":"10.4158\/EP.9.6.544_bb0240","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1001\/jama.280.7.605","article-title":"Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women","volume":"280","author":"Hulley","year":"1998","journal-title":"JAMA."},{"key":"10.4158\/EP.9.6.544_bb0245","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-117-1-1","article-title":"Treatment of postmenopausal osteoporosis with transdermal estrogen","volume":"117","author":"Lufkin","year":"1992","journal-title":"Ann Intern Med."},{"key":"10.4158\/EP.9.6.544_bb0250","doi-asserted-by":"crossref","first-page":"897","DOI":"10.7326\/0003-4819-130-11-199906010-00005","article-title":"The effect of low-dose continuous estrogen and progesterone therapy with calcium and vitamin D on bone in elderly women: a randomized, controlled trial","volume":"130","author":"Recker","year":"1999","journal-title":"Ann Intern Med."},{"key":"10.4158\/EP.9.6.544_bb0255","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJM198011203032102","article-title":"Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen","volume":"303","author":"Weiss","year":"1980","journal-title":"N Engl J Med"},{"key":"10.4158\/EP.9.6.544_bb0260","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1210\/er.2001-5002","article-title":"Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women","volume":"23","author":"Wells","year":"2002","journal-title":"Endocr Rev."},{"key":"10.4158\/EP.9.6.544_bb0265","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women","volume":"288","author":"Writing Group for the Women\u2019s Health Initiative Investigators","year":"2002","journal-title":"JAMA."},{"key":"10.4158\/EP.9.6.544_bb0270","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N Enel J Med."},{"key":"10.4158\/EP.9.6.544_bb0275","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1359\/jbmr.2003.18.1.9","article-title":"The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis","volume":"18","author":"Orwoll","year":"2003","journal-title":"J Bone Miner Res."},{"key":"10.4158\/EP.9.6.544_bb0280","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1080\/01926230252929882","article-title":"Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety","volume":"30","author":"Vahle","year":"2002","journal-title":"Toxicol Pathol."},{"key":"10.4158\/EP.9.6.544_bb0285","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1001\/jama.281.23.2189","article-title":"The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial; Multiple Outcomes of Raloxifene Evaluation [erratum in JAMA. 1999;282:2124]","volume":"281","author":"Cummings","year":"1999","journal-title":"JAMA."},{"key":"10.4158\/EP.9.6.544_bb0290","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1056\/NEJM199712043372301","article-title":"Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women","volume":"337","author":"Delmas","year":"1997","journal-title":"N Engl J Med."},{"key":"10.4158\/EP.9.6.544_bb0295","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.282.7.637","article-title":"(Multiple Outcomes of Raloxifene Evaluation [MORE] Investigators). Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial","volume":"282","author":"Ettinger","year":"1999","journal-title":"JAMA."},{"key":"10.4158\/EP.9.6.544_bb0300","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa031975","article-title":"The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis","volume":"349","author":"Black","year":"2003","journal-title":"N Engl J Med."},{"key":"10.4158\/EP.9.6.544_bb0305","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1056\/NEJMoa035725","article-title":"The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. [comment]","volume":"349","author":"Finkelstein","year":"2003","journal-title":"N Engl J Med."},{"key":"10.4158\/EP.9.6.544_bb0310","first-page":"3076","article-title":"Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: a randomized, controlled clinical trial","volume":"84","author":"Lindsay","year":"1999","journal-title":"J Clin Endocrinol Metab."},{"key":"10.4158\/EP.9.6.544_bb0315","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/S0140-6736(97)02342-8","article-title":"Randomised controlled study of effect of parathyroid hormone on vertebral- bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis","volume":"350","author":"Lindsay","year":"1997","journal-title":"Lancet."},{"key":"10.4158\/EP.9.6.544_bb0320","doi-asserted-by":"crossref","first-page":"935","DOI":"10.7326\/0003-4819-131-12-199912210-00005","article-title":"Alendronate and estrogen-progestin in the long-term prevention of bone loss: four-year results from the early postmenopausal intervention cohort study; a randomized, controlled trial","volume":"131","author":"Ravn","year":"1999","journal-title":"Ann Intern Med."},{"key":"10.4158\/EP.9.6.544_bb0325","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/BF01623465","article-title":"A prospective study of thiazide use and fractures in women","volume":"7","author":"Feskanich","year":"1997","journal-title":"Osteoporos Int."},{"issue":"Suppl 1","key":"10.4158\/EP.9.6.544_bb0330","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1007\/s002239900379","article-title":"Ipriflavone prevents the loss of bone mass in pharmacological menopause induced by GnRH-ago- nists","volume":"61","author":"Gambacciani","year":"1997","journal-title":"Calcif Tissue Int."},{"key":"10.4158\/EP.9.6.544_bb0335","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0378-5122(97)00059-5","article-title":"Effects of combined low dose of the isoflavone derivative ipriflavone and estrogen replacement on bone mineral density and metabolism in postmenopausal women","volume":"28","author":"Gambacciani","year":"1997","journal-title":"Maturitas."},{"key":"10.4158\/EP.9.6.544_bb0340","first-page":"9","article-title":"Effect of ipri- flavone\u2014a synthetic derivative of natural isoflavones\u2014on bone mass loss in the early years after menopause","volume":"5","author":"Gennari","year":"1998","journal-title":"Menopause."},{"key":"10.4158\/EP.9.6.544_bb0345","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1210\/endo.140.4.6663","article-title":"Selective effects of genistein, a soybean isoflavone, on B-lymphopoiesis and bone loss caused by estrogen deficiency","volume":"140","author":"Ishimi","year":"1999","journal-title":"Endocrinology."},{"key":"10.4158\/EP.9.6.544_bb0350","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1359\/jbmr.1997.12.5.806","article-title":"Prevention of postmenopausal bone loss using tibolone or conventional peroral or transdermal hormone replacement therapy with 17beta-estradiol and dydroges- terone","volume":"12","author":"Lippuner","year":"1997","journal-title":"J Bone Miner Res."},{"key":"10.4158\/EP.9.6.544_bb0355","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s001980050041","article-title":"Fluoride salts are no better at preventing new vertebral fractures than calcium-vitamin D in postmenopausal osteoporosis: the FAVO Study","volume":"8","author":"Meunier","year":"1998","journal-title":"Osteoporos Int."},{"key":"10.4158\/EP.9.6.544_bb0360","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1002\/jbmr.5650110502","article-title":"Slow-release sodium fluoride in osteoporosis","volume":"11","author":"Pak","year":"1996","journal-title":"J Bone Miner Res."},{"key":"10.4158\/EP.9.6.544_bb0365","doi-asserted-by":"crossref","first-page":"230","DOI":"10.3109\/09513599909167560","article-title":"Double-blind, placebo-controlled study of the effects of tibolone on bone mineral density in postmenopausal osteoporotic women with and without previous fractures","volume":"13","author":"Pavlov","year":"1999","journal-title":"Gynecol Endocrinol."},{"key":"10.4158\/EP.9.6.544_bb0370","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-129-1-199807010-00001","article-title":"The effect of sodium monofluorophosphate plus calcium on vertebral fracture rate in postmenopausal women with moderate osteoporosis: a randomized, controlled trial","volume":"129","author":"Reginster","year":"1998","journal-title":"Ann Intern Med."},{"issue":"4 Pt 1","key":"10.4158\/EP.9.6.544_bb0375","first-page":"574","article-title":"A randomized study of tibolone on bone mineral density in osteoporotic postmenopausal women with previous fractures","volume":"92","author":"Studd","year":"1998","journal-title":"Obstet Gynecol."},{"key":"10.4158\/EP.9.6.544_bb0380","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1532-5415.2000.tb02641.x","article-title":"(Fracture Intervention Trial Research Group). Prevalent vertebral deformities predict mortality and hospitalization in older women with low bone mass","volume":"48","author":"Ensrud","year":"2000","journal-title":"J Am Geriatr Soc."},{"key":"10.4158\/EP.9.6.544_bb0385","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s001980050075","article-title":"Hosking DJ (Nottingham EPIC Study Group). Cigarette smoking, alcohol and caffeine consumption, and bone mineral density in postmenopausal women","volume":"8","author":"Grainge","year":"1998","journal-title":"Osteoporos Int."},{"key":"10.4158\/EP.9.6.544_bb0390","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1001\/archinte.159.11.1215","article-title":"Palermo L, Nevitt MC, Genant HK, Cummings SR (Study of Osteoporotic Fractures Research Group). Vertebral fractures and mortality in older women: a prospective study","volume":"159","author":"Kado","year":"1999","journal-title":"Arch Intern Med."},{"key":"10.4158\/EP.9.6.544_bb0395","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/BF02672517","article-title":"Influence of fracture criteria on the outcome of a randomized trial of therapy","volume":"8","author":"Melton","year":"1998","journal-title":"Osteoporos Int."},{"key":"10.4158\/EP.9.6.544_bb0400","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1359\/jbmr.1997.12.1.24","article-title":"Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation","volume":"12","author":"Ray","year":"1997","journal-title":"J Bone Miner Res."},{"key":"10.4158\/EP.9.6.544_bb0405","first-page":"1897","article-title":"Percutaneous polymethylmethacrylate verte- broplasty in the treatment of osteoporotic vertebral body compression fractures: technical aspects","volume":"18","author":"Jensen","year":"1997","journal-title":"Am J Neuro-radiol."},{"key":"10.4158\/EP.9.6.544_bb0410","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1056\/NEJM200011233432101","article-title":"Prevention of hip fracture in elderly people with use of a hip protector","volume":"343","author":"Kannus","year":"2000","journal-title":"N Enel J Med."},{"key":"10.4158\/EP.9.6.544_bb0415","doi-asserted-by":"crossref","first-page":"28","DOI":"10.2188\/jea.8.28","article-title":"Relationship between exercise and bone mineral density among over 5,000 women aged 40 years and above","volume":"8","author":"Kano","year":"1998","journal-title":"J Epidemiol."},{"key":"10.4158\/EP.9.6.544_bb0420","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1001\/jama.282.7.687","article-title":"Therapy for fracture prevention","volume":"282","author":"McClung","year":"1999","journal-title":"JAMA."},{"key":"10.4158\/EP.9.6.544_bb0425","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/j.1742-1241.1999.tb11682.x","article-title":"Evidence-based medicine and osteoporosis: a comparison of fracture risk reduction data from osteoporosis randomised clinical trials","volume":"53","author":"Meunier","year":"1999","journal-title":"Int J Clin Pract."},{"key":"10.4158\/EP.9.6.544_bb0430","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1001\/jama.289.15.1957","article-title":"Prevention of hip fracture by external hip protectors: a randomized controlled trial","volume":"289","author":"van Schoor","year":"2003","journal-title":"JAMA"},{"key":"10.4158\/EP.9.6.544_bb0435","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s001980050109","article-title":"The effect of exercise training programs on bone mass: a meta-analysis of published controlled trials in pre-and postmenopausal women","volume":"9","author":"Wolff","year":"1999","journal-title":"Osteoporos Int."}],"updated-by":[{"DOI":"10.4158\/ep.14.6.802","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2008,9,1]],"date-time":"2008-09-01T00:00:00Z","timestamp":1220227200000}}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X2040312X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X2040312X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/aace.metapress.com\/index\/DG06TDBLJ25WWWE7.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:43:59Z","timestamp":1761515039000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X2040312X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,11]]},"references-count":87,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2003,11]]}},"alternative-id":["S1530891X2040312X"],"URL":"https:\/\/doi.org\/10.4158\/ep.9.6.544","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2003,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"American Association of Clinical Endocrinologists Medical Guidelines For Clinical Practice For The Prevention and Treatment of Postmenopausal Osteoporosis: 2001 Edition, With Selected Updates For 2003","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.4158\/EP.9.6.544","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2003 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}